SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Janssen Research & Development Release: New One-Year Phase 3 Study Results Show Anti-TNF SIMPONI® Maintained Clinical Response in Treatment of Moderately to Severely Active Ulcerative Colitis